Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Relapsed or refractory primary DLBCL of the CNS
DLBCL
DRUG: Tislelizumab|DRUG: Pemetrexed
Objective response rate, To evaluate objective response rate (ORR) of tislelizumab (BGB-A317) plus pemetrexed in R/R primary DLBCL of the CNS, Through study completion, an average of 1 year
Progression-free survival, To evaluate progression-free survival (PFS), duration of response (DoR) and overall survival (OS) of tislelizumab plus pemetrexed in R/R primary DLBCL of the CNS, Through study completion, an average of 1 year|Safety and Tolerability, To evaluate the safety and tolerability of tislelizumab plus pemetrexed based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 5.0, Through study completion, an average of 1 year|Overall survival, The length of time from the date of the first treatment to the date of any death or last follow-up, Through study completion, an average of 2 years
This is a multi-center, open label, single arm, phase 2 study designed to evaluate efficacy and safety of tislelizumab (BGB-A317) in combination with pemetrexed in patients with R/R primary DLBCL of the CNS. Twenty-eight patients will be enrolled. Eligible participants will receive combination treatment until disease progression, unacceptable toxicity, or withdrawal of informed consent.